In addition, sphingosine kinase-1 (SK1)-mediated ERK activation was triggered in sunitinib-resistant RCC cell lines which were resensitized to sunitinib using SK1 and ERK pharmacological inhibitors (Gao and Deng, 2014). Here, SPHK1 is linked to renal cell adenocarcinoma.